Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

212 Pb ADVC 001

Next Previous
Drug Profile

212 Pb ADVC 001

Alternative Names: 212-lead ADVC 001; 212Pb ADVC001; [212Pb]Pb-ADVC001

Latest Information Update: 01 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advancell
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
  • 26 Jun 2023 POINT Biopharma and AdvanCell agree to co-develop 212Pb radioisotope and radioligand
  • 15 Mar 2023 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, In adults, In the elderly, Metastatic disease, Second-line therapy or greater) in Australia (IV) (NCT05720130)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top